1. Pink Sheet

Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program

 
• By Cathy Kelly

Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.

Pharma On A Litigation Blitz Against Negotiation Program • Source: Shutterstock

The US government violated the Administrative Procedures Act by expanding the statutory definition of “qualifying single source drug,” and adding a new “bona fide marketing” requirement in its guidance implementing the Medicare price negotiation program, AstraZeneca PLC argues in a lawsuit against the US government filed in Delaware district court 25 August.

The complaint, which also claims the Centers for Medicare and Medicaid Services violated the Fifth Amendment of the Constitution’s due...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.